Yüklüyor......
Novel agents and strategies for overcoming EGFR TKIs resistance
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target, EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR mutations, which has been a major breakthrough for lung cancer treatment.. The progression-free survival (PFS) of patients...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3898214/ https://ncbi.nlm.nih.gov/pubmed/24410791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2162-3619-3-2 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|